CD8A and neoplasm: In mice, several chemotherapeutic agents, including the anthracycline doxorubicin, result in ICD and lead to antitumor responses that depend on DCs and CD8+ T cells.12 18 Similarly, both DCs and CD8+ T cells have been previously demonstrated to contribute to tumor control following radiotherapy.13 19 Our study provides further evidence for the immunogenicity of some anticancer therapies,11 12 showing that their potency is reduced in mice lacking T (and B) cells.